

***Fiscal Year 2023 Department of Defense Peer Reviewed Medical Research Program (PRMRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Trial Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-PRMRP-CTA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • <i>Preproposal submission is required; application submission is by invitation only.</i> • Supports the rapid implementation of clinical trials of novel interventions with the potential to have a significant impact on patient care in the topic area(s) of interest. • Proposed projects may range from small proof-of-concept trials through large-scale, definitive trials. • Two options will be offered: <ul style="list-style-type: none"> ○ <u>Planning Phase with Clinical Trial Option:</u> Provides support to prepare and submit an Investigational New Drug/ Investigational Device Exemption (IND/ IDE) application to the U.S. Food and Drug Administration (FDA) and requires FDA/regulatory approval or exemption to proceed before the clinical trial may be funded. ○ <u>Clinical Trial Only Option:</u> Provides support for the clinical trial. IND or IDE applications to the FDA, if needed, must be approved by the FDA and included in the application submission. 	<p><u>Clinical Trial:</u></p> <ul style="list-style-type: none"> • A funding limit is not defined; requested funding must be appropriate for the scope of work proposed. • The maximum period of performance for the clinical trial is 4 years. <p><u>Planning Phase with Clinical Trial Option:</u></p> <ul style="list-style-type: none"> • The maximum allowable funding for the Planning Phase period of performance is \$500,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance for the planning phase is 18 months. • The maximum period of performance for the clinical trial is 4 years. 	<p>Pre-Application (Preproposal): April 12, 2023 5:00 p.m. Eastern time</p> <p>Application: July 19, 2023 11:59 p.m. Eastern time</p>
<p>Discovery Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-PRMRP-DA</p>	<p>Postdoctoral fellow or clinical fellow (or equivalent) and above</p>	<ul style="list-style-type: none"> • Supports the exploration of a highly innovative new concept or untested theory. • Not intended to support the logical progression of an already established line of questioning. • <i>Clinical trials will not be funded.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$200,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Letter of Intent): March 29, 2023 5:00 p.m. Eastern time</p> <p>Application: April 26, 2023 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Focused Program Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-PRMRP-FPA</p>	<p>Full Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • <i>Preproposal submission is required; application submission is by invitation only.</i> • Supports a synergistic, multidisciplinary research program of at least four distinct but complementary projects addressing an overarching goal/question. • Projects should work together to answer critical questions, resolve differing hypotheses, and translate laboratory findings to clinical applications. • Projects may range from exploratory/hypothesis-developing studies through small-scale clinical trials that together will address the overarching goal/question. • Research team of highly qualified, multidisciplinary project leaders should be led by an investigator with demonstrated success in directing large, focused projects. 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$7.2 million for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): April 12, 2023 5:00 p.m. Eastern time</p> <p>Application: July 19, 2023 11:59 p.m. Eastern time</p>
<p>Investigator-Initiated Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-PRMRP-IIRA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • Supports research that will make an original and important contribution to the field of research or patient care in the Topic Area(s) of interest. • Partnering Principal Investigator Option available. • <i>Clinical trials will not be funded.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1.6 million for direct costs for single investigators and \$2.0 million for partnering investigators. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): April 19, 2023 5:00 p.m. Eastern time</p> <p>Application: May 31, 2023 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Lifestyle and Behavioral Health Interventions Research Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-PRMRP-LBIRA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • Supports the development, evaluation, and implementation of therapies, technologies, and innovations that will enhance patient experience and improve outcomes. • Projects may include clinical research or clinical trials for <i>interventions that do not require regulation by the FDA</i>. • Encourages patient advocate participation in the research team. • <i>Animal studies will not be funded.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$3.0 million for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): April 19, 2023 5:00 p.m. Eastern time</p> <p>Application: May 31, 2023 11:59 p.m. Eastern time</p>
<p>Technology/Therapeutic Development Award</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>HT9425-23-PRMRP-TTDA</p>	<p>Assistant Professor level or above (or equivalent)</p>	<ul style="list-style-type: none"> • Supports the translation of promising preclinical findings into clinical applications for prevention, detection, diagnosis, treatment, and/or quality of life. • Supports product-oriented projects (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. • Two funding levels are available depending on the maturity of the product. The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level: <ul style="list-style-type: none"> ○ Funding Level 1: Supports research that is supported by significant preliminary data but has not advanced to the level of clinical translation. ○ Funding Level 2: Supports research that is in the final states of preclinical development with potential for near-term clinical development. Applications must provide relevant data that support the rationale for the proposed study. Funding Level 2 recipients must submit or obtain an IND/IDE application to the FDA, or must transition the product to clinical practice, within the period of performance. • <i>Clinical trials will not be funded.</i> 	<p>Funding Level 1:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$2.0 million for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. <p>Funding Level 2:</p> <ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$4.0 million for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Letter of Intent): April 19, 2023 5:00 p.m. Eastern time</p> <p>Application: May 31, 2023 11:59 p.m. Eastern time</p>